- Brainomix has won the world’s first national tender for its e-Stroke platform, which will be rolled out to all stroke centers in Hungary as part of the National Institute for Health Development’s initiative to improve stroke care
- Funded under the EU4Health programme, this is the first such national tender where a one-shot AI imaging platform will be deployed across a national healthcare system .
OXFORD, UK, September 1, 2022 – Brainomix, the AI-powered medical technology solutions company, today announces that it has won the national tender in Hungary to deploy its imaging software in all stroke centers in Hungary as part of the National Institute for Health Development Initiative to improve stroke care.
Awarded following a competitive process, the 5-year program is funded under the EU4Health program and is the first time that a single-stroke AI imaging platform will be deployed across an entire country.
This latest tender will build on a previous EU grant that funded the installation of Brainomix’s flagship e-Stroke platform in 10 hospitals in and around the Hungarian city of Pécs. It will allow e-Stroke to be deployed in the remaining 28 stroke centers of the Hungarian National Health System, with the support of eRAD, which will act as a technology partner.
e-Stroke is a collection of tools that use state-of-the-art AI algorithms to assist physicians by providing real-time interpretation of brain scans to help guide treatment and referral decisions for stroke patients , allowing more patients to be treated in the right place at the right time.
The initiative to use AI to improve stroke care and patient outcomes for the benefit of all stroke patients in Hungary was led by world renowned neuroscientist Professor István Szikora of the National Institute of Mental Health, Neurology and Neurosurgery (OMIII) in Budapest, which will serve as the national stroke center with full program supervision.
The Hungarian e-Stroke program was unveiled at the start of the Hungarian Stroke Society xvi. Congress and XIII Conference of the Hungarian Society of Neurosonology, taking place in Siófok, from September 1 to 3, 20221.
Launching the programme, Professor Dr Szikora said: “Each year more than 20,000 stroke patients are admitted to hospitals across Hungary. e-Stroke has been shown to enable faster treatment times, facilitating better patient outcomes, as has been piloted in unique sites here in Hungary and reported in other countries including the UK and Poland.
During our first experience with e-Stroke, we were particularly impressed with its comprehensive suite of imaging solutions, with the ability to be used in small general hospitals as well as large stroke centers. We are pleased that with the support of an EU grant (EFOP 5.2.6-20), this option is now available in several stroke centers across the country.
The e-Stroke platform will help specialist and non-specialist clinicians interpret stroke brain scans in real time and identify patients who need urgent treatment or referral to a specialist hospital. Using the e-Stroke mobile app, doctors can securely share brain scans with specialists in other hospitals, bringing expert decision-making to all hospital emergency departments 24/7 .
The e-Stroke platform has been in use for four years at the Semmelweis University Hospital in Budapest, where the main stroke center treats more than 700 stroke patients every year. Dr. Bence Gunda, neurologist and associate professor based in the Semmelweis Department of Neurology, previously shown treatment rates for stroke patients have improved and treatment times have been reduced following the installation of Brainomix e-Stroke.
Dr Gunda said: “Our results are indicative of the impact Brainomix’s technology can have on a stroke network, helping doctors make decisions faster so that more patients can benefit from the optimal treatment. e-Stroke aids in the diagnosis of acute ischemic stroke by quantifying the extent of ischemic damage, indicating where occluded vessels are, and assessing the status of collateral circulation. The CT infusion module is very useful in assessing the eligibility of patients with a late time window for thrombectomy. »
In addition to the full national tender for Hungary, e-Stroke has been adopted by other countries in Europe, including throughout Andalusia in Spain and, in 2021, Brainomix won the national tender for 17 of the largest comprehensive stroke centers in Poland. United Kingdom, Brainomix won an NHS Artificial Intelligence in Health and Care Award to roll out e-Stroke in a number of UK stroke networks and assess its impact on stroke care in NHS regions.
Since its launch in 2015, e-Stroke is now used in more than 330 hospitals in 30 countries, and it is estimated that every 4 seconds a stroke patient benefits from the information provided by its AI-powered software.
Dr. Michalis Papadakis, CEO and co-founder of Brainomix, said, “We are absolutely delighted that e-Stroke has been chosen to help improve stroke care in Hungary. This further demonstrates the superiority of our e-Stroke platform and strengthens our position as market leader in Europe. Rollout across Hungary has already begun, with plans to install and train in all 38 hospitals over the next few months, highlighting the speed and ease of installation and our ability to deploy e-Stroke at scale.
“AI is transforming healthcare in so many ways, and we’re proud to be pioneering AI-powered imaging solutions in precision medicine for better treatment decisions not just for stroke. but also for other indications, including pulmonary fibrosis and cancer,” added Dr Papadakis.
1. Brainomix Symposium, September 1, 2022, 10:15-11:15 a.m., the Hungarian Stroke Society xvi. Congress and XIII Conference of the Hungarian Society of Neurosonology, Siófok (Hungary).
Caption: Prof Dr István Szikora of the National Institute of Mental Health, Neurology and Neurosurgery (OMIII), Budapest
Brainomix specializes in creating AI-powered software solutions to enable precision medicine to make better treatment decisions in stroke, pulmonary fibrosis and cancer. A spin-off from the University of Oxford, Brainomix is a rapidly growing commercial company that has pioneered award-winning imaging biomarkers and software solutions used in more than 30 countries around the world. Its first product, the e-Stroke platform, offers clinicians the most comprehensive stroke imaging solution, accelerating treatment times and improving patient functional independence. Its pipeline includes new imaging biomarkers for better treatment of pulmonary fibrosis and cancer, and its technology is used by pharmaceutical companies to improve the success of clinical trials.
A private company, headquartered in Oxford, UK. Brainomix investors include Boehringer Ingelheim Venture Fund, Parkwalk Advisors, Tencent Holdings and Oxford University Innovation Fund.
Jeff Wyrtzen, Director of Marketing and Business Development
+44 (0)7927 164210
T +44 (0)1865 582730
Sue Charles, Charles Consultants
+44 (0)7968 726585